Race/Ethnicity-specific Disparities in In-Hospital Mortality and Hospital Charges Among Inflammatory Bowel Disease-related Hospitalizations in the United States.

Race/Ethnicity-specific Disparities in In-Hospital Mortality and Hospital Charges Among Inflammatory Bowel Disease-related Hospitalizations in the United States. J Clin Gastroenterol. 2019 Apr 17;: Authors: Galoosian A, Rezapour M, Liu B, Bhuket T, Wong RJ Abstract GOAL: The goal of this study was to evaluate disparities in hospital outcomes among inflammatory bowel disease (IBD) related hospitalizations in the United States with a focus on ethnicity-specific disparities. BACKGROUND: IBD-related hospitalizations contribute to significant morbidity and health care economic burden. METHODS: IBD-related hospitalizations (identified with ICD-9) among US adults were evaluated using 2007…

Read More

Fecal Lactoferrin for Assessment of Inflammatory Bowel Disease Activity: A Systematic Review and Meta-Analysis.

Fecal Lactoferrin for Assessment of Inflammatory Bowel Disease Activity: A Systematic Review and Meta-Analysis. J Clin Gastroenterol. 2019 Apr 15;: Authors: Dai C, Jiang M, Sun MJ, Cao Q Abstract OBJECTIVE: Persistent disease activity is associated with a poor prognosis in inflammatory bowel disease (IBD) patients. Therefore, monitoring of IBD activity can avoid the poor prognosis. Serum biomarkers reflect a summation of systemic host responses rather than being specific for intestinal inflammation. And endoscopic monitoring is invasive, costly, and time consuming. The objective of our study was to perform a…

Read More

Risk Factors for Gastrointestinal Symptoms Following Successful Eradication of Clostridium difficile by Fecal Microbiota Transplantation (FMT).

Risk Factors for Gastrointestinal Symptoms Following Successful Eradication of Clostridium difficile by Fecal Microbiota Transplantation (FMT). J Clin Gastroenterol. 2019 Mar 13;: Authors: Allegretti JR, Kassam Z, Fischer M, Kelly C, Chan WW Abstract BACKGROUND: Fecal microbiota transplantation (FMT) is a promising therapy for recurrent Clostridioides difficile infection (CDI). Many patients report altered bowel habits including constipation, bloating, gas and loose stool post-FMT despite resolution of CDI, and the etiology remains unclear. METHODS: This was a prospective cohort study of adult patients with recurrent CDI who underwent FMT (1) via…

Read More

Thirty Years of Lactobacillus rhamnosus GG: A Review.

Thirty Years of Lactobacillus rhamnosus GG: A Review. J Clin Gastroenterol. 2019 Mar;53 Suppl 1:S1-S41 Authors: Capurso L Abstract Lactobacillus rhamnosus GG (LGG) was the first strain belonging to the genus Lactobacillus to be patented in 1989 thanks to its ability to survive and to proliferate at gastric acid pH and in medium containing bile, and to adhere to enterocytes. Furthermore LGG is able to produces both a biofilm that can mechanically protect the mucosa, and different soluble factors beneficial to the gut by enhancing intestinal crypt survival, diminishing apoptosis…

Read More

Variations in Insurances Policies Regarding Adherence to the AGA Guideline for Therapeutic Drug Monitoring in IBD.

Variations in Insurances Policies Regarding Adherence to the AGA Guideline for Therapeutic Drug Monitoring in IBD. J Clin Gastroenterol. 2018 Nov 14;: Authors: Yadav A, Vasquez P, Dolgin NH, Falchuk KR, Feuerstein JD Abstract BACKGROUND: The American Gastroenterological Association (AGA) published guidelines on therapeutic drug monitoring (TDM) in inflammatory bowel disease (IBD) in August 2017 recommending use of reactive TDM to guide treatment changes in patients with active IBD who are being treated with anti-tumor necrosis factor (anti-TNF) agents or thiopurines. We sought to determine if changes in national clinical…

Read More

Financial Toxicity in Crohn’s Disease.

Financial Toxicity in Crohn’s Disease. J Clin Gastroenterol. 2018 Oct 24;: Authors: Voit A, Cross RK, Bellavance E, Bafford AC Abstract BACKGROUND: A patient-reported outcome measure called Comprehensive Score for Financial Toxicity (COST) was previously developed and validated in patients with cancer. GOALS: We sought to assess the financial toxicity associated with Crohn’s disease (CD) by administering the COST questionnaire to patients treated at a tertiary care center. STUDY: Forty-eight patients diagnosed with CD completed questionnaires, which included the COST quality of life instrument as well as questions with regard…

Read More

Narrow Band Imaging for Surveillance in Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis.

Narrow Band Imaging for Surveillance in Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis. J Clin Gastroenterol. 2018 Aug 09;: Authors: Lv XH, Wang BL, Cao GW Abstract BACKGROUND: The role of narrow band imaging (NBI) for surveillance colonoscopy in patients with inflammatory bowel disease (IBD) is debatable. We aim to compare NBI versus other endoscopic techniques in surveillance of IBD basing on current evidences. METHODS: A systematic search of PubMed, Embase, and the Cochrane Library databases was conducted for relevant studies. To assess the detection efficacy, we estimated risk…

Read More

Hepatotoxicity of Inflammatory Bowel Disease Medications.

Hepatotoxicity of Inflammatory Bowel Disease Medications. J Clin Gastroenterol. 2018 Jul 20;: Authors: Shamberg L, Vaziri H Abstract Various medications used to treat inflammatory bowel diseases have been implicated to cause hepatotoxicity. These include sulfasalazine, 5-aminosalicylic acids, fluoroquinolones, metronidazole, thiopurines, methotrexate, anti-tumor necrosis factor agents, and alpha-4 integrin inhibitors. Various types of liver injury have been reported in association with these medications including hypersensitivity reaction, hepatocellular or cholestatic disease, nodular regenerative hyperplasia, liver fibrosis/cirrhosis, portal hypertension and autoimmune liver injury. The revised Roussel Uclaf Causality Assessment Method (RUCAM) provides a…

Read More

Probiotics in Pediatric Gastroenterology: Emerging Indications: Inflammatory Bowel Diseases.

Probiotics in Pediatric Gastroenterology: Emerging Indications: Inflammatory Bowel Diseases. J Clin Gastroenterol. 2018 Jul 20;: Authors: Scarpato E, Russo M, Staiano A Abstract Etiology of inflammatory bowel disease (IBD) is not yet completely understood, but it is hypothesized that a disruption of the immune tolerance to gut microbiota, due to several potential factors like an abnormal gut microbiota composition and activity, may lead to IBD occurrence. Manipulation of the intestinal microbiota is an attractive target for the management of IBD, and probiotics could be useful to influence the disease’s course.…

Read More
<< Go Back